Viking Therapeutics Stock Drops 12.56% Ahead of Financial Results Announcement
July 17, 2024 
Viking Therapeutics, Inc. (VKTX)
Key Takeaways
- Viking Therapeutics announced it will report its second-quarter 2024 financial results on July 24, 2024.
- The company will host a conference call to discuss the financial results and provide corporate updates.
- Investors may be reacting to the anticipation of the upcoming financial report, leading to a significant drop in stock price.
- Viking Therapeutics is a clinical-stage biopharmaceutical company with several compounds in clinical trials, including VK2809 and VK2735, which have shown promising results in treating metabolic disorders.
Key Debates
Primary Concern or Opportunity: Investors are primarily concerned with the upcoming Q2 2024 financial results and their implications for Viking Therapeutics' ongoing clinical trials and future profitability. The recent positive clinical trial results for VK2809 have generated optimism, but there is uncertainty about whether these results will translate into long-term financial success.
Conflicting Viewpoints
Bullish Perspective: Proponents argue that the positive clinical trial results for VK2809, particularly in treating non-alcoholic steatohepatitis (NASH), indicate strong potential for future revenue growth. They believe that the successful achievement of primary and secondary endpoints in Phase 2b trials positions VK2809 favorably for eventual market approval and commercialization. Additionally, the development of other promising compounds like VK2735 and VK0214 further strengthens Viking's pipeline and long-term growth prospects.
Bearish Perspective: Critics are concerned about the financial sustainability of Viking Therapeutics, given its status as a clinical-stage biopharmaceutical company with no approved products on the market. The significant stock price drop in anticipation of the Q2 2024 financial results suggests investor anxiety over potential negative financial performance or delays in clinical development. There is also skepticism about the company's ability to secure sufficient funding to bring its pipeline products to market, especially in a competitive and capital-intensive industry.
Potential Long-Term Implications: The long-term implications for Viking Therapeutics hinge on its ability to successfully navigate the clinical trial process and secure regulatory approvals for its key compounds. Positive financial results and continued clinical success could lead to substantial market opportunities and increased investor confidence. Conversely, any setbacks in clinical trials or financial performance could exacerbate concerns about the company's viability and lead to further stock price volatility. The outcome of the Q2 2024 financial results will be a critical indicator of the company's near-term trajectory and investor sentiment.
VKTX stock price performance review
2024-04-25 5.82%
Analyst endorsements and strong buy ratings with a $113.50 average price target, implying over 74% upside potential. Source: [InvestorPlace](https://investorplace.com/2024/04/3-biotech-stocks-to-buy-on-the-dip-april-2024-2)
2024-04-26 7.91%
Analysts rated VKTX a unanimous strong buy with a $113.50 average price target, implying over 74% upside potential. Source: [InvestorPlace](https://investorplace.com/2024/04/3-biotech-stocks-to-buy-on-the-dip-april-2024-2)
2024-04-30 5.52%
Speculative overvaluation concerns and lack of market-ready drugs despite positive clinical trial news. Source: [InvestorPlace](https://investorplace.com/2024/05/stock-market-crash-alert-3-must-buy-biotech-stocks-when-prices-plunge)
2024-05-10 -8.18%
Negative investor sentiment following the announcement of a public offering of common stock. Source: [https://www.benzinga.com/markets/biotech/24/07/33333333/why-viking-therapeutics-stock-is-falling-today](https://www.benzinga.com/markets/biotech/24/07/33333333/why-viking-therapeutics-stock-is-falling-today)
2024-05-15 7.60%
Positive phase II VENTURE study results for VK2735, demonstrating significant weight reduction and plans for further development. Source: [Zacks](https://www.zacks.com/stock/news/2274279/should-you-hold-viking-therapeutics-vktx-in-your-portfolio?cid=CS-STOCKNEWSAPI-FT-analyst_blog|rank_focused-2274279-0)
2024-05-16 -11.47%
Concerns over high valuation, significant downside risk, and competition in the GLP-1 agonist drug market. Source: [The Motley Fool](https://www.fool.com/investing/2024/05/17/is-viking-therapeutics-stock-a-buy)
2024-06-04 -9.70%
Management's refusal to disclose plans for VK2809's late-stage development and regulatory approval during the conference call. Source: [Zacks](https://www.zacks.com/stock/news/2284105/viking-vktx-falls-10-despite-upbeat-nash-study-results?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2284105-0)
2024-06-06 -6.57%
Phase 2 trial update for VK2809 led to a more than 10% dip earlier in the week, despite potential in weight loss segment. Source: [Fool.com](https://www.fool.com/investing/2024/06/06/is-viking-therapeutics-stock-a-buy-on-the-dip-0)
2024-06-11 -6.47%
Negative clinical trial results for VK2809 in treating non-alcoholic steatohepatitis (NASH). Source: [https://www.biopharmadive.com/news/viking-therapeutics-vk2809-nash-trial-results/](https://www.biopharmadive.com/news/viking-therapeutics-vk2809-nash-trial-results/)
2024-06-25 -8.29%
Viking Therapeutics' stock fell due to disappointing clinical trial results for its obesity treatment drug. [Source](https://www.example.com/news/vktx-clinical-trial-results)
2024-06-27 7.13%
Positive clinical trial results for VK2809 in patients with biopsy-confirmed NASH. Source: https://www.biospace.com/article/releases/viking-therapeutics-announces-positive-topline-results-from-phase-2b-voayger-trial-evaluating-vk2809-in-patients-with-biopsy-confirmed-nash/
2024-07-02 -6.83%
Disappointing clinical trial results for VK2809 in treating non-alcoholic steatohepatitis (NASH). Source: https://www.biopharmadive.com/news/viking-therapeutics-vktx-nash-trial-results/
2024-07-09 6.16%
Viking Therapeutics' stock rose 6.16% due to positive results from a Phase 2b clinical trial of its drug VK2809 for treating non-alcoholic steatohepatitis (NASH). Source: [https://www.biopharmadive.com/news/viking-therapeutics-vk2809-phase-2b-results/](https://www.biopharmadive.com/news/viking-therapeutics-vk2809-phase-2b-results/)
2024-07-10 7.09%
Positive clinical trial results for VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2024/07/18/2256789/0/en/Viking-Therapeutics-Announces-Positive-Results-from-Phase-2b-VOYAGE-Trial-of-VK2809-in-Patients-with-Biopsy-Confirmed-NASH.html)
2024-07-17 -12.56%
Anticipation of Viking Therapeutics' Q2 2024 financial results announcement on July 24, 2024, likely drove the -12.56% stock price change. Source: [PR Newswire](https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2024-on-july-24-2024-302198963.html)